Leukemia, B-Cell  >>  Gazyva (obinutuzumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
GALTON, NCT01300247: A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Checkmark Presentation of data from GALTON (GA 101+bendamustine combo & FC chemotherapy) trial in previously untreated chronic lymphocytic leukemia at ASH
Nov 2013 - Nov 2013: Presentation of data from GALTON (GA 101+bendamustine combo & FC chemotherapy) trial in previously untreated chronic lymphocytic leukemia at ASH
Completed
1
41
US
Fludarabine, Obinutuzumab, RO5072759; GA101, Bendamustine, Cyclophosphamide
Genentech, Inc.
Lymphocytic Leukemia, Chronic
01/13
12/15
NCT01680991: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Completed
1
48
RoW
Obinutuzumab, RO5072759, GA101
Hoffmann-La Roche
Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
12/14
12/14
NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Recruiting
1
70
US, Europe
GDC-0199 (ABT-199), Obinutuzumab
Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd
Lymphocytic Leukemia, Chronic
01/15
11/16

Download Options